AU2018379255B2 - Bis-choline tetrathiomolybdate for treating Wilson Disease - Google Patents

Bis-choline tetrathiomolybdate for treating Wilson Disease Download PDF

Info

Publication number
AU2018379255B2
AU2018379255B2 AU2018379255A AU2018379255A AU2018379255B2 AU 2018379255 B2 AU2018379255 B2 AU 2018379255B2 AU 2018379255 A AU2018379255 A AU 2018379255A AU 2018379255 A AU2018379255 A AU 2018379255A AU 2018379255 B2 AU2018379255 B2 AU 2018379255B2
Authority
AU
Australia
Prior art keywords
bis
choline tetrathiomolybdate
dose
level
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018379255A
Other languages
English (en)
Other versions
AU2018379255A1 (en
Inventor
Aftab ALA
Frederick ASKARI
Carl BJARTMAR
Anna CZLONKOWSKA
Peter Ferenci
Peter HEDERA
Michael SCHILSKY
Karl-Heinz Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharma International Operations ULC
Original Assignee
Alexion Pharma International Operations ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma International Operations ULC filed Critical Alexion Pharma International Operations ULC
Publication of AU2018379255A1 publication Critical patent/AU2018379255A1/en
Application granted granted Critical
Publication of AU2018379255B2 publication Critical patent/AU2018379255B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2018379255A 2017-12-04 2018-12-04 Bis-choline tetrathiomolybdate for treating Wilson Disease Active AU2018379255B2 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762594184P 2017-12-04 2017-12-04
US62/594,184 2017-12-04
US201862646553P 2018-03-22 2018-03-22
US62/646,553 2018-03-22
US201862655568P 2018-04-10 2018-04-10
US62/655,568 2018-04-10
US201862669095P 2018-05-09 2018-05-09
US62/669,095 2018-05-09
US201862741313P 2018-10-04 2018-10-04
US62/741,313 2018-10-04
US201862750595P 2018-10-25 2018-10-25
US62/750,595 2018-10-25
PCT/EP2018/083551 WO2019110619A1 (en) 2017-12-04 2018-12-04 Bis-choline tetrathiomolybdate for treating wilson disease

Publications (2)

Publication Number Publication Date
AU2018379255A1 AU2018379255A1 (en) 2020-06-25
AU2018379255B2 true AU2018379255B2 (en) 2024-10-17

Family

ID=64661349

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018379255A Active AU2018379255B2 (en) 2017-12-04 2018-12-04 Bis-choline tetrathiomolybdate for treating Wilson Disease

Country Status (17)

Country Link
US (3) US11510944B2 (enExample)
EP (3) EP4029498B1 (enExample)
JP (3) JP2021505655A (enExample)
KR (1) KR102803161B1 (enExample)
AU (1) AU2018379255B2 (enExample)
BR (1) BR112020011055A2 (enExample)
CA (1) CA3084100A1 (enExample)
DK (2) DK3720433T3 (enExample)
ES (2) ES2912306T3 (enExample)
FI (1) FI4029498T3 (enExample)
HU (2) HUE071155T2 (enExample)
IL (1) IL275115B2 (enExample)
MX (1) MX2020006284A (enExample)
PL (2) PL3720433T3 (enExample)
PT (2) PT4029498T (enExample)
SI (2) SI3720433T1 (enExample)
WO (1) WO2019110619A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
AU2018379255B2 (en) 2017-12-04 2024-10-17 Alexion Pharma International Operations Unlimited Company Bis-choline tetrathiomolybdate for treating Wilson Disease
EP3749417A1 (en) 2018-02-06 2020-12-16 Alexion Pharma International Operations Unlimited Company Crystalline particles of bis-choline tetrathiomolybdate
JP2023502389A (ja) 2019-11-21 2023-01-24 アレクシオン ファーマシューティカルズ, インコーポレイテッド ウィルソン病患者における神経損傷を低下させるための方法
US20240044920A1 (en) * 2020-09-11 2024-02-08 Alexion Pharmaceuticals, Inc. Anti-ceruloplasmin antibodies and uses thereof
CA3172751A1 (en) * 2020-11-13 2022-05-19 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
JP2024505229A (ja) * 2021-01-31 2024-02-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 銅代謝関連疾患又は障害を治療するための新規製剤
JP2024532131A (ja) * 2021-08-17 2024-09-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 銅代謝関連疾患又は障害を治療する方法
AU2023427396A1 (en) 2023-01-30 2025-08-21 Alexion Pharmaceuticals, Inc. Tetrathiomolybdic acid for use in treating copper metabolism-associated diseases or disorders (wilson disease)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
EP1539131A4 (en) * 2002-07-23 2009-07-08 Univ Michigan TETRAPROPYLAMMONIUM TETRATHIOMOLYBDATE AND RELATED COMPOUNDS FOR ANTI-ANGIOGENOUS THERAPIES
AU2007205996A1 (en) * 2006-01-10 2007-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
AU2018379255B2 (en) 2017-12-04 2024-10-17 Alexion Pharma International Operations Unlimited Company Bis-choline tetrathiomolybdate for treating Wilson Disease
EP3749417A1 (en) 2018-02-06 2020-12-16 Alexion Pharma International Operations Unlimited Company Crystalline particles of bis-choline tetrathiomolybdate

Also Published As

Publication number Publication date
WO2019110619A1 (en) 2019-06-13
PL4029498T3 (pl) 2025-06-02
KR20200096798A (ko) 2020-08-13
CA3084100A1 (en) 2019-06-13
KR102803161B1 (ko) 2025-05-07
PL3720433T3 (pl) 2022-07-18
EP3720433A1 (en) 2020-10-14
EP4029498A1 (en) 2022-07-20
MX2020006284A (es) 2021-04-12
US20230070534A1 (en) 2023-03-09
JP2023075247A (ja) 2023-05-30
AU2018379255A1 (en) 2020-06-25
SI3720433T1 (sl) 2022-09-30
ES2912306T3 (es) 2022-05-25
JP2021505655A (ja) 2021-02-18
DK4029498T3 (da) 2025-04-28
IL275115B1 (en) 2025-06-01
US20210177894A1 (en) 2021-06-17
US12233088B2 (en) 2025-02-25
US20210137972A1 (en) 2021-05-13
PT3720433T (pt) 2022-05-03
EP4029498B1 (en) 2025-02-05
HUE058921T2 (hu) 2022-09-28
US11510944B2 (en) 2022-11-29
IL275115A (en) 2020-07-30
EP3720433B1 (en) 2022-02-02
DK3720433T3 (da) 2022-05-02
EP4523745A3 (en) 2025-05-14
PT4029498T (pt) 2025-05-06
RU2020122023A (ru) 2022-01-10
SI4029498T1 (sl) 2025-07-31
EP4523745A2 (en) 2025-03-19
FI4029498T3 (fi) 2025-04-29
JP2025066802A (ja) 2025-04-23
ES3026756T3 (en) 2025-06-12
HUE071155T2 (hu) 2025-08-28
BR112020011055A2 (pt) 2020-11-17
IL275115B2 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
US12233088B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
US11419832B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
JP2024180450A (ja) 5-ht2bアゴニストの形成を阻害するための製剤およびその使用方法
CN103974619B (zh) 治疗法布里病的给药方案
JP2024081667A (ja) ポンペ病の処置のための投与計画
US11793776B1 (en) Methods of administering solriamfetol to lactating women
US20250082674A1 (en) Methods of treating copper metabolism-associated diseases or disorders
RU2787632C2 (ru) Бис-холина тетратиомолибдат для лечения болезни вильсона
US20220071938A1 (en) Treatment of hyperammonemia in patients with renal insufficiency
CA3230084A1 (en) Methods of treating copper metabolism-associated diseases or disorders
CN116234555A (zh) 改良形式的曲美他嗪的改良释放制剂
WO2024162974A1 (en) Tetrathiomolybdic acid for use in treating copper metabolism-associated diseases or disorders (wilson disease)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)